BRAF and susceptibility to pneumonia measurement: One reported case describes a metastatic NSCLC patient with poor performance status who had BRAF V600E mutation and developed severe pneumonia two weeks after initiating tyrosine kinase inhibitor therapy (dabrafenib and trametinib), ultimately resulting in death [4].